(57 days)
Permanent root canal filling in combination with gutta-percha points in case of inflamed or necrotic pulp. Permanent root canal filling in combination with gutta-percha points following a retreatment procedure.
BioRoot™ Flow 0.5g, BioRoot™ Flow 2g is hydrophilic mineral root canal sealer presented as a ready-to-use paste in a syringe. BioRoot™ Flow 0.5g, BioRoot™ Flow 2g is based on a tricalcium silicate reaction with in situ water to seal the root canal. The sealer ensures a good adaptation to the root canal, tight interface with gutta-percha point and an adequate radiopacity. It is an implantable medical device intended to be used in dentistry. It is part of endodontic cements used as permanent root canal sealer. BioRoot™ Flow 0.5g. BioRoot™ Flow 2g is used in combination with gutta-percha points to fill the root canal.
This document, K212283, is a 510(k) summary for a medical device called "BioRoot™ Flow 0.5g, BioRoot™ Flow 2g" manufactured by Septodont. It describes a root canal filling resin. The document establishes substantial equivalence to predicate devices based on non-clinical and clinical testing, primarily focusing on physical-chemical properties and functional characteristics.
Here's an analysis based on the provided text, addressing your questions:
1. A table of acceptance criteria and the reported device performance
The document does not explicitly state "acceptance criteria" in a quantitative format for specific performance metrics that were tested for the new device. Instead, it presents a side-by-side comparison of the subject device (BioRoot™ Flow) with its predicate devices (BioRoot™ RCS and iRoot SP) and claims "substantial equivalence" based on various characteristics. The performance reported is essentially the successful demonstration of this equivalence through bench testing and by leveraging clinical data from the predicate.
Here's a table based on the provided "Side-by-Side Comparison" section, highlighting where performance is discussed implicitly:
| Characteristic | BioRoot™ Flow 0.5g, BioRoot™ Flow 2g (Subject Device) | BioRoot™ RCS (Primary Predicate) | iRoot SP (Secondary Predicate) | Similarities and Differences / Performance (Implied Acceptance) |
|---|---|---|---|---|
| Classification device code | KIF | KIF | KIF | Same; Substantially Equivalent |
| Classification Name | Resin, Root canal filling | Resin, Root canal filling | Resin, Root canal filling | Same; Substantially Equivalent |
| Class | Class II | Class II | Class II | Same; Substantially Equivalent |
| Intended Use | Permanent root canal sealer | Permanent root canal sealer | Permanent root canal sealer | Same; Substantially Equivalent |
| Indications | Permanent root canal filling in combination with gutta-percha points in case of inflamed or necrotic pulp. Permanent root canal filling in combination with gutta-percha points following a retreatment procedure. | Permanent root canal filling in combination with gutta-percha points in case of inflamed or necrotic pulp. Permanent root canal filling in combination with gutta-percha points following a retreatment procedure. BioRoot™ RCS is suitable for use in single cone technique or cold lateral condensation. | Permanent obturation of the root canal following vital pulp-extirpation. Permanent obturation of the root canal following removal of infected or necrotic pulp and placement of intracanal dressings. | iRoot SP - Similar, indications statement does not mention gutta-percha points. BioRoot™ RCS – Similar, does not include the statement regarding being suitable for use in single cone technique or cold lateral condensation (due to the change in design, obturation is no longer limited to specific techniques). Implied Acceptance: The differences are considered minor and do not raise new questions of safety or effectiveness. |
| Intended Users | Dental healthcare professional. | Dental healthcare professional. | Dental healthcare professional. | Same, Substantially Equivalent |
| Intended Patient Population | Permanent and mature teeth | Permanent and mature teeth | Permanent and mature teeth | Same, Substantially Equivalent |
| Prescription/over-the-counter use | Prescription | Prescription | Prescription | Same, Substantially Equivalent |
| Single-use/multiple use | Multi-Use Device (only the tips are considered single use) | Single Use Device (The bottle of powder is multi-use, whereas the single dose containers are single use) | Multi-Use | iRoot SP - Same; Substantially Equivalent. BioRoot™ RCS - Different; container closure system is different due to different delivery system. Implied Acceptance: This difference in use model is not deemed to impact substantial equivalence. |
| Galenic Forms (Delivery System) | Paste (paste syringe) | Powder/Liquid (powder liquid mixing) | Paste (paste syringe) | iRoot SP - Same; Substantially Equivalent. BioRoot™ RCS - Different; container closure system is different due to different delivery system. Implied Acceptance: Differences in delivery system are acceptable given other equivalences. |
| Ingredients and quantities | Paste (per 100g): Tricalcium silicate (36.07g), Zirconium oxide (30.00g), Calcium carbonate (3.50g), Propylene glycol (27.93g), Polyvidone K90 (1.00g), Sepineo P600 (1.00g), Aerosil R1812S (0.50g) | Powder (per 100g): Micronized C3S (30.00g), Tricalcium silicate (30.00g), Zirconium oxide (35.00g), Polyvidone K90 (5.00g). Liquid (per 100g): Dihydrated Calcium Chloride (29.40g), Neomere Tech (2.00g), Purified water (68.60g) | Paste: Tricalcium silicate, Dicalcium silicate, Calcium Phosphate, Zirconium oxide, Calcium hydroxide, Solvent, Gelifying Agent, Stabilizer. Quantities are unknown as this is proprietary information. | Performance: "The ingredients contained in BioRoot™ Flow... and iRoot SP are similar and determined to be substantially equivalent." "BioRoot™ Flow... has similar ingredients to BioRoot™ RCS with a few additional ingredients to allow for the paste. The quantities also differ... however once reconstituted the cements have the same amount of Tricalcium silicate and Zirconium oxide (approx. 66%) indicating an equivalent composition. Performance reports have demonstrated substantial equivalence." |
| Operations (Mixing and Dispensing) | No mixing required, product is a ready-to-use paste | Mixing: liquid added to powder and mixed by hand by the dentist. | No mixing required, product is a ready-to-use paste | iRoot SP - Same; Substantially Equivalent. BioRoot™ RCS - Different; mixing is required. Implied Acceptance: Simpler operation is a difference but does not prevent equivalence. |
| Consistency | Paste | Not Performed (not a paste) | Paste | iRoot SP - Same; Substantially Equivalent |
| Setting Time | 1h to 6h | 55min to 300min | 4h | Performance: "Performance testing have demonstrated that BioRoot™ Flow... is substantially equivalent to BioRoot™ RCS and iRoot SP sealer regarding setting time." |
| Additional Performance Claim | "BioRoot™ Flow... has undergone extensive bench testing to provide evidence that its physical-chemical properties are substantially equivalent to the predicate devices, BioRoot™ RCS and iRoot SP. All three (3) devices are provided non-sterile, have comparable setting time, sealing and adhesion." | Not specified in detail. | Not specified in detail. | Implied Acceptance: Comparable sealing and adhesion demonstrated. |
| Biocompatibility | "Biocompatibility test results determined that considering all existing data resulting from the chemical characterization and associated toxicological risk assessment, and from biological data, the biocompatibility profile of BioRoot™ Flow 0.5g, BioRoot™ Flow 2g can be considered acceptable when used as intended." | Not specified in detail, but implied as a predicate. | Not specified in detail, but implied as a predicate. | Implied Acceptance: Biocompatibility is acceptable. |
2. Sample sizes used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)
The document primarily relies on non-clinical bench testing for the new device and equivalence to a predicate that likely had clinical data.
- Test Set Sample Size: The document does not specify the sample sizes for the bench tests conducted on BioRoot™ Flow. It states "extensive bench testing" and that results demonstrated "substantial equivalence" for physical-chemical properties, setting time, sealing, and adhesion.
- Data Provenance: The document does not specify the country of origin of the data nor whether the studies were retrospective or prospective. Given it's a 510(k), regulatory submissions typically rely on a mix of existing data and new testing. The reference to "existing data" for biocompatibility suggests some retrospective component, but the bench testing would be prospective for the new device.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)
The document does not mention using experts to establish ground truth for a test set. This device is a dental material, and its equivalence is based on physical, chemical, and biological properties, not interpretative tasks (like image reading) that would require expert consensus for ground truth.
4. Adjudication method (e.g. 2+1, 3+1, none) for the test set
Not Applicable. Since there is no mention of expert review or interpretation of data in a way that would require adjudication (e.g., in an image-based diagnostic study), no adjudication method is specified.
5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
No MRMC study was done. This is a root canal filling material, not an AI-assisted diagnostic device. The "clinical testing" mentioned (Section 8) refers to demonstrating clinical equivalence to the primary predicate based on the predicate's existing clinical data, rather than performing new clinical trials for the subject device. It states, "Clinical evaluation data obtained using the equivalent device, BioRoot™ RCS, was used to support clinical evidence of BioRoot™ Flow 0.5g, BioRoot™ Flow 2g and can be extended to BioRoot™ Flow 0.5g, BioRoot™ Flow 2g in terms of clinical performance and clinical safety."
6. If a standalone (i.e. algorithm only without human-in-the loop performance) was done
Not Applicable. This is a physical medical device (root canal sealer), not an algorithm or software. Therefore, the concept of "standalone performance" for an algorithm does not apply.
7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)
For the non-clinical bench testing of the subject device (BioRoot™ Flow), the "ground truth" would be established by standardized laboratory testing procedures and predefined specifications for material properties (e.g., setting time measurement according to ISO standards, or specific measurements for sealing and adhesion). For biocompatibility, it's based on chemical characterization and toxicological risk assessment, and biological data (likely in vitro and/or in vivo animal studies as per ISO 10993).
For the claim of clinical equivalence, the "ground truth" for the predicate device's clinical performance would have been established through its own clinical studies and outcomes data, which are then leveraged for the new device by demonstrating substantial equivalence in technology and intended use.
8. The sample size for the training set
Not Applicable. This document describes a traditional medical device (dental material), not an AI/ML product that would have a "training set."
9. How the ground truth for the training set was established
Not Applicable. As there is no AI/ML component, there is no training set or associated ground truth establishment process for that purpose.
{0}------------------------------------------------
Image /page/0/Picture/0 description: The image shows the logos of the Department of Health & Human Services and the Food and Drug Administration (FDA). The Department of Health & Human Services logo is on the left, and the FDA logo is on the right. The FDA logo includes the letters "FDA" in a blue box, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in blue text.
September 16, 2021
Septodont Greg Montgomery Business Operations Manager 205 Granite Run Drive, Suite 150 Lancaster, Pennsylvania 17601
Re: K212283
Trade/Device Name: BioRoot Flow 0.5g, BioRoot Flow 2g Regulation Number: 21 CFR 872.3820 Regulation Name: Root Canal Filling Resin Regulatory Class: Class II Product Code: KIF Dated: July 19, 2021 Received: July 21, 2021
Dear Greg Montgomery:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part
{1}------------------------------------------------
801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4. Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Michael E. Adjodha, M.ChE. Assistant Director DHT1B: Division of Dental and ENT Devices OHT1: Office of Ophthalmic, Anesthesia, Respiratory, ENT and Dental Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
Indications for Use
510(k) Number (if known) K212283
Device Name BioRoot Flow 0.5g, BioRoot Flow 2g
Indications for Use (Describe)
- · Permanent root canal filling in combination with gutta-percha points in case of inflamed or necrotic pulp.
- · Permanent root canal filling in combination with gutta-percha points following a retreatment procedure.
| Type of Use (Select one or both, as applicable) |
|---|
| ------------------------------------------------- |
| ☑ Prescription Use (Part 21 CFR 801 Subpart D) |
|---|
| ☐ Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{3}------------------------------------------------
5. 510(K) Summary K212283
Septodont BioRoot™ Flow 0.5q. BioRoot™ Flow 2q (per 21 CFR 807.93)
1. SUBMITTER/510(K) HOLDER
Septodont 58, rue du Pont De Créteil Saint-Maur des Fossés Cedex Phone: 331-49-76-71-16 Establishment Registration No: 9610964
Contact: Leslie Fillion, Regulatory Affairs Manager Contact Phone: 1-519-623-4800 Ext. 6354 Contact Email: Ifillion@septodont.com Date Prepared: July 13, 2021
2. DEVICE NAME
BioRoot™ Flow 0.5g, BioRoot™ Flow 2g Device Name: Device Classification Name: Resin, Root Canal Filling/Dental Cement Regulation Number: Primary: 872.3820, Secondary: 872.3250 Classification Product Code: KIF Device Class: Class II
3. PREDICATE DEVICE
Primary Predicate
| Manufacturer: | Septodont |
|---|---|
| Device Name: | BioRoot TM RCS |
| Device Classification Name: | Resin, Root Canal Filling/Dental Cement |
| 510(k) Number: | K130601 |
| Regulation Number: | Primary: 872.3820, Secondary: 872.3250 |
| Classification Product Code: | KIF |
| Device Class: | Class II |
Secondary Predicate
| Manufacturer: | Innovative BioCeramix Inc |
|---|---|
| Device Name: | iRoot SP |
| Device Classification Name: | Resin, Root Canal Filling/Dental Cement |
| 510(k) Number: | K080917 |
| Regulation Number: | Primary: 872.3820, Secondary: 872.3250 |
| Classification Product Code: | KIF |
| Device Class: | Class II |
{4}------------------------------------------------
4. DEVICE DESCRIPTION
BioRoot™ Flow 0.5g, BioRoot™ Flow 2g is hydrophilic mineral root canal sealer presented as a ready-to-use paste in a syringe. BioRoot™ Flow 0.5g, BioRoot™ Flow 2g is based on a tricalcium silicate reaction with in situ water to seal the root canal. The sealer ensures a good adaptation to the root canal, tight interface with gutta-percha point and an adequate radiopacity.
It is an implantable medical device intended to be used in dentistry. It is part of endodontic cements used as permanent root canal sealer. BioRoot™ Flow 0.5g. BioRoot™ Flow 2g is used in combination with gutta-percha points to fill the root canal.
5. INDICATION FOR USE/INTENDED USE
The intended use for BioRoot™ Flow 0.5g, BioRoot™ Flow 2g is:
-
Permanent root canal sealer .
The indications for BioRoot™ Flow 0.5g, BioRoot™ Flow 2g are: -
Permanent root canal filling in combination with gutta-percha points in case of . inflamed or necrotic pulp.
-
Permanent root canal filling in combination with gutta-percha points following . a retreatment procedure.
6. SUMMARY OF TECHNOLOGICAL CHARACTERISTICS COMPARED TO THE PREDICATE DEVICES
Septodont demonstrated that BioRoot™ Flow 0.5g. BioRoot™ Flow 2q is substantially equivalent to the predicate devices, BioRoot™ RCS (K130601, cleared 17-Oct-2013) and iRoot SP (K080917, cleared 09-Apr-2008), in regards to the indications and basic design principles. The indications, technological characteristics and overall design of the subject device are substantially equivalent to those of the predicate devices, with any differences limited to minor differences in design and performance that do not raise any new questions of safety or effectiveness.
7. SUMMARY OF NON-CLINICAL PERFORMANCE TESTING AS BASIS FOR SUBSTANTIAL EQUIVALENCE
BioRoot™ Flow 0.5g, BioRoot™ Flow 2g has undergone extensive bench testing to provide evidence that its physical-chemical properties are substantially equivalent to the predicate devices, BioRoot™ RCS and iRoot SP. All three (3) devices are provided non-sterile, have comparable setting time, sealing and adhesion.
Biocompatibility test results determined that considering all existing data resulting from the chemical characterization and associated toxicological risk assessment.
{5}------------------------------------------------
and from biological data, the biocompatibility profile of BioRoot™ Flow 0.5g, BioRoot™ Flow 2g can be considered acceptable when used as intended.
8. SUMMARY OF CLINICAL TESTING AS BASIS FOR SUBSTANTIAL EQUIVALENCE
Clinical equivalence between BioRoot™ Flow 0.5g, BioRoot™ Flow 2g and the primary predicate, BioRoot™ RCS, was demonstrated based on equivalence in terms of the intended use, indications for use, technical, mechanical and biological properties. Furthermore, BioRoot™ Flow 0.5g, BioRoot™ Flow 2g and BioRoot™ RCS are used for the same clinical indication, at the same site in the body (root canal of the tooth), are in contact with the same tissues (root canal dentine), in the same population (mature and permanent teeth) and have the same clinical performance in regards to the expected clinical effect for a specific intended purpose. Clinical evaluation data obtained using the equivalent device, BioRoot™ RCS, was used to support clinical evidence of BioRoot™ Flow 0.5g, BioRoot™ Flow 2g and can be extended to BioRoot™ Flow 0.5g, BioRoot™ Flow 2g in terms of clinical performance and clinical safety.
9. CONCLUSIONS DRAWN FROM NON-CLINICAL AND CLINICAL TESTS
The subject device, BioRoot™ Flow 0.5g, BioRoot™ Flow 2g, and its' predicate devices, BioRoot™ RCS and iRoot SP, have demonstrated to be substantially equivalent and have comparable chemical, physical and performance specifications. Based on the above information and the data provided, the subject device has demonstrated to be substantially equivalent to both the primary predicate device, BioRoot™ RCS (K130601, cleared 17-Oct-2013), and the secondary predicate device, iRoot SP (K080917, cleared 09-Apr-2008).
| Characteristic | BioRoot™ Flow 0.5g,BioRoot™ Flow 2g(Subject Device) | BioRoot™ RCS(Primary PredicateDevice - K130601) | iRoot SP(Secondary PredicateDevice - K080917) | Similarities andDifferences betweenSubject Device andPredicate Devices |
|---|---|---|---|---|
| Manufacturer | Septodont | Septodont | Innovative BioCeramixInc. | N/A |
| Classificationdevice code | KIF | KIF | KIF | Same; SubstantiallyEquivalent |
| ClassificationName | Resin, Root canal filling | Resin, Root canalfilling | Resin, Root canalfilling | Same; SubstantiallyEquivalent |
| Class | Class II | Class II | Class II | Same; SubstantiallyEquivalent |
| IntendedUse | Permanent root canalsealer | Permanent root canalsealer | Permanent rootcanal sealer | Same, SubstantiallyEquivalent |
| Characteristic | BioRoot™ Flow 0.5g,BioRoot™ Flow 2g(Subject Device) | BioRoot™ RCS(Primary PredicateDevice - K130601) | iRoot SP(Secondary PredicateDevice - K080917) | Similarities andDifferences betweenSubject Device andPredicate Devices |
| Indications | Permanent root canalfilling in combinationwith gutta-percha pointsin case of inflamed ornecrotic pulp.Permanent root canalfilling in combinationwith gutta-percha pointsfollowing a retreatmentprocedure. | Permanent root canalfilling in combinationwith gutta-perchapoints in case ofinflamed or necroticpulp.Permanent root canalfilling in combinationwith gutta-perchapoints following aretreatment procedure.BioRoot™ RCS issuitable for use insingle cone techniqueor cold lateralcondensation. | Permanent obturationof the root canalfollowing vital pulp-extirpation.Permanent obturationof the root canalfollowing removal ofinfected ornecrotic pulp andplacement ofintracanal dressings. | iRoot SP - Similar,indications statementdoes not mention gutta-percha pointsBioRoot™ RCS –Similar, does notinclude the statementregarding being suitablefor use in single conetechnique or cold lateralcondensation (due tothe change in design,obturation is no longerlimited to specifictechniques). |
| IntendedUsers | Dental healthcareprofessional. | Dental healthcareprofessional. | Dental healthcareprofessional. | Same, SubstantiallyEquivalent |
| IntendedPatientPopulation | Permanent and matureteeth | Permanent and matureteeth | Permanent andmature teeth | Same, SubstantiallyEquivalent |
| Prescription/over-the-counter use | Prescription | Prescription | Prescription | Same, SubstantiallyEquivalent |
| Single-use/multiple use | Multi-Use Device (onlythe tips are consideredsingle use) | Single Use Device(The bottle of powderis multi-use, whereasthe single dosecontainers are singleuse) | Multi-Use | iRoot SP - Same;Substantially Equivalent |
| GalenicForms(DeliverySystem) | Paste(paste syringe) | Powder/Liquid(powder liquid mixing) | Paste(paste syringe) | iRoot SP - Same;Substantially Equivalent |
| Characteristic | BioRoot™ Flow 0.5g,BioRoot™ Flow 2g(Subject Device) | BioRoot™ RCS(Primary PredicateDevice - K130601) | iRoot SP(Secondary PredicateDevice - K080917) | Similarities andDifferences betweenSubject Device andPredicate Devices |
| Ingredientsandquantities | Paste (per 100g):• Tricalcium silicate(36.07g)• Zirconium oxide(30.00g)• Calcium carbonate(3.50g)• Propylene glycol(27.93g)• Polyvidone K90(1.00g)• Sepineo P600(1.00g)• Aerosil R1812S(0.50g) | Powder (per 100g):• Tricalcium silicate -Micronized C3S(30.00g)• Tricalcium silicate(30.00g)• Zirconium oxide(35.00g)• Polyvidone K90(5.00g)Liquid (per 100g):• Dihydrated CalciumChloride (29.40g)• Neomere Tech(2.00g)• Purified water(68.60g) | Paste:• Tricalcium silicate• Dicalcium silicate• CalciumPhosphate• Zirconium oxide• Calcium hydroxide• Solvent• Gelifying Agent• StabilizerQuantities areunknown as this isproprietaryinformation. | The ingredientscontained inBioRoot™ Flow 0.5g,BioRoot™ Flow 2g andiRoot SP are similar anddetermined to besubstantially equivalent.BioRoot™ Flow 0.5g,BioRoot™ Flow 2gperformance testing hasdemonstratedsubstantial equivalenceto BioRoot™ RCS.BioRoot™ Flow 0.5g,BioRoot™ Flow 2g hassimilar ingredients toBioRoot™ RCS with afew additionalingredients to allow forthe paste. Thequantities also differbetween the twodevices however oncereconstituted thecements have the sameamount of Tricalciumsilicate and Zirconiumoxide (approx. 66%)indicating an equivalentcomposition.Performance reportshave demonstratedsubstantial equivalence(refer to Section 18). |
| Containers | Premixed paste iscontained in a syringe | Powder is packaged ina capsule; liquid ispackaged in a singledose container | Premixed paste iscontained in asyringe | iRoot SP - Same;Substantially EquivalentBioRoot™ RCS -Different; containerclosure system isdifferent due to differentdelivery systemiRoot SP - Same;Substantially Equivalent |
| Operations(Mixing andDispensing) | No mixing required,product is a ready-to-use paste | Mixing: liquid added topowder and mixed byhand by the dentist. | No mixing required,product is a ready-to-use paste | iRoot SP - Same;Substantially Equivalent |
| Characteristic | BioRoot™ Flow 0.5g,BioRoot™ Flow 2g(Subject Device) | BioRoot™ RCS(Primary PredicateDevice - K130601) | iRoot SP(Secondary PredicateDevice - K080917) | Similarities andDifferences betweenSubject Device andPredicate Devices |
| BioRoot™ RCS -Different; mixing isrequired as it requiresreconstitution of thepowder and liquid. | ||||
| Consistency | Paste | Not Performed (not apaste) | Paste | iRoot SP - Same;Substantially Equivalent |
| SettingTime | 1h to 6h | 55min to 300min | 4h | Performance testinghave demonstrated thatBioRoot™ Flow 0.5g,BioRoot™ Flow 2g issubstantially equivalentto BioRoot™ RCS andiRoot SP sealerregarding setting time. |
Side-by-Side Comparison of BioRoot™ Flow 0.5q, BioRoot™ Flow 2q with BioRoot™RCS and iRoot SP
{6}------------------------------------------------
{7}------------------------------------------------
{8}------------------------------------------------
§ 872.3820 Root canal filling resin.
(a)
Identification. A root canal filling resin is a device composed of material, such as methylmethacrylate, intended for use during endodontic therapy to fill the root canal of a tooth.(b)
Classification. (1) Class II if chloroform is not used as an ingredient in the device.(2) Class III if chloroform is used as an ingredient in the device.
(c)
Date PMA or notice of completion of a PDP is required. A PMA or a notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before December 26, 1996 for any root canal filling resin described in paragraph (b)(2) of this section that was in commercial distribution before May 28, 1976, or that has, on or before December 26, 1996 been found to be substantially equivalent to a root canal filling resin described in paragraph (b)(2) of this section that was in commercial distribution before May 28, 1976. Any other root canal filling resin shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.